[go: up one dir, main page]

SV2002000291A - Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto ref. pc10794ajnm/bb - Google Patents

Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto ref. pc10794ajnm/bb

Info

Publication number
SV2002000291A
SV2002000291A SV2001000291A SV2001000291A SV2002000291A SV 2002000291 A SV2002000291 A SV 2002000291A SV 2001000291 A SV2001000291 A SV 2001000291A SV 2001000291 A SV2001000291 A SV 2001000291A SV 2002000291 A SV2002000291 A SV 2002000291A
Authority
SV
El Salvador
Prior art keywords
compound
syntheize
separation
ref
target compound
Prior art date
Application number
SV2001000291A
Other languages
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000291A publication Critical patent/SV2002000291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE AL COMPUESTO (+)-6-[AMINO-(6-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4-(3-CLORO-FENIL)-1-CICLOPROPILMETIL-1H-QUINOLEIN-2-ONA, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES DEL MISMO, Y PROFARMACOS DEL MISMO, Y AL USO DE DICHOS COMPUESTOS PARA INHIBIR UN DESARROLLO CELULAR NORMAL, INCLUYENDO EL CANCER, EN ANIMALES MAMIFEROS. EL INVENTO SE REFIERE TAMBIEN A METODOS UTILES PARA SINTETIZAR EL SUSODICHO COMPUESTO.
SV2001000291A 2000-01-21 2001-01-22 Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto ref. pc10794ajnm/bb SV2002000291A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17771800P 2000-01-21 2000-01-21

Publications (1)

Publication Number Publication Date
SV2002000291A true SV2002000291A (es) 2002-07-16

Family

ID=22649709

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000291A SV2002000291A (es) 2000-01-21 2001-01-22 Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto ref. pc10794ajnm/bb

Country Status (17)

Country Link
US (1) US6479513B2 (es)
EP (1) EP1248782A1 (es)
JP (2) JP2003520796A (es)
AR (1) AR029792A1 (es)
AU (1) AU2001214087A1 (es)
BR (1) BR0016986A (es)
CA (1) CA2398353C (es)
CO (1) CO5271702A1 (es)
GT (1) GT200100008A (es)
HN (1) HN2000000266A (es)
MX (1) MXPA02007153A (es)
MY (1) MY126069A (es)
PA (1) PA8508101A1 (es)
PE (1) PE20011118A1 (es)
SV (1) SV2002000291A (es)
TN (1) TNSN01009A1 (es)
WO (1) WO2001053289A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
JP4351445B2 (ja) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
US20030139332A1 (en) * 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ES2287466T3 (es) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
DK1585743T3 (da) * 2002-12-19 2007-09-17 Pfizer 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ES2346986T3 (es) * 2004-05-03 2010-10-22 Janssen Pharmaceutica Nv Proceso de sintesis diastereoselectiva con 6-bromo-4-(3-clorofenil)-2-methoxi-quinolina.
CN100567290C (zh) 2004-05-03 2009-12-09 詹森药业有限公司 锂化n-甲基咪唑在亚磺基亚胺上的非对映选择性加成
CA2563807C (en) 2004-05-03 2012-11-20 Janssen Pharmaceutica N.V. Diastereoselective synthesis process for the preparation of imidazole compounds
MX2007002312A (es) 2004-08-26 2007-04-16 Pfizer Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
DK1784396T3 (da) * 2004-08-26 2011-02-14 Pfizer Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US8062838B2 (en) 2005-09-20 2011-11-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CL2007002404A1 (es) 2006-08-21 2008-04-18 Hoffmann La Roche Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (ja) 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110217309A1 (en) 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP3383375A1 (en) 2015-12-03 2018-10-10 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
HK1039123A1 (zh) 1998-08-27 2002-04-12 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉-2-酮衍生物
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Also Published As

Publication number Publication date
AR029792A1 (es) 2003-07-16
HN2000000266A (es) 2001-05-21
GT200100008A (es) 2001-10-19
MY126069A (en) 2006-09-29
JP2003520796A (ja) 2003-07-08
TNSN01009A1 (fr) 2005-11-10
MXPA02007153A (es) 2002-12-13
WO2001053289A1 (en) 2001-07-26
CO5271702A1 (es) 2003-04-30
CA2398353A1 (en) 2001-07-26
US6479513B2 (en) 2002-11-12
EP1248782A1 (en) 2002-10-16
PE20011118A1 (es) 2001-11-06
BR0016986A (pt) 2002-10-08
AU2001214087A1 (en) 2001-07-31
JP2007326868A (ja) 2007-12-20
US20020004514A1 (en) 2002-01-10
PA8508101A1 (es) 2002-08-26
CA2398353C (en) 2007-07-31

Similar Documents

Publication Publication Date Title
SV2002000291A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto ref. pc10794ajnm/bb
DE60037586D1 (de) Zellwachstumsinhibition
CU23263B7 (es) COMPUESTOS DE PIRROLO [2,3-d] PIRIMIDINA
ECSP045239A (es) Composicion de ziprasidona y controles sinteticos
ES2134051T3 (es) Procedimiento para la preparacion de sildenafil.
WO2004027822A3 (en) Oriented nanostructures and methods of preparing
WO2005047898A3 (en) Methods and compositions for identifying therapeutic compounds
WO2008001101A3 (en) Pharmaceutical combinations
WO2004050030A3 (en) Anti-sickling agents
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
PT1633697E (pt) Processo para a produção de compostos substituídos de 3-arilbutilamina
WO2002009754A1 (en) Novel remedies for cancer
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
WO2002069895A3 (en) Heterocyclic analgesic compounds and methods of use thereof
WO2004004635A3 (en) Radiolabeled compounds and liposomes and their methods of making and using the same
CR8350A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica
EA200200101A1 (ru) Получение замещенных пиперидин-4-онов
PT1347984E (pt) Processo para a preparacao de derivados de taxano
WO2005097087A3 (en) Merged ion channel modulating compounds and uses thereof
WO2001070684A3 (en) Peptidomimetic ligands for cellular receptors and ion channels
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
WO2005021733A3 (en) Methods and compositions for sirna expression

Legal Events

Date Code Title Description
FD Lapse